Type I interferons (α/β) in immunity and autoimmunity

Annual Review of Immunology

Volumn 23, Issue , 2005, Pages 307-336

  Theofilopoulos, Argyrios N ^a   Baccala, Roberto ^a   Beutler, Bruce ^a   Kono, Dwight H ^a  

^a SCRIPPS RESEARCH INSTITUTE   (United States)

Author keywords

IDDM; Innate immunity; Lupus; Plasmacytoid cells; TLR

Indexed keywords

ALPHA INTERFERON; BETA INTERFERON; TOLL LIKE RECEPTOR;

AUTOIMMUNE DISEASE; AUTOIMMUNE HEMOLYTIC ANEMIA; AUTOIMMUNITY; CELLULAR IMMUNITY; CLINICAL TRIAL; CYTOKINE PRODUCTION; CYTOLOGY; DENDRITIC CELL; DRUG MECHANISM; HUMAN; HUMORAL IMMUNITY; IMMUNE RESPONSE; IMMUNITY; INNATE IMMUNITY; INSULIN DEPENDENT DIABETES MELLITUS; MULTIPLE SCLEROSIS; MYASTHENIA GRAVIS; NONHUMAN; PLASMA CELL; PRIORITY JOURNAL; REVIEW; SIGNAL TRANSDUCTION; SYSTEMIC LUPUS ERYTHEMATOSUS;

ADAPTATION, PHYSIOLOGICAL; ANIMALS; AUTOIMMUNE DISEASES; AUTOIMMUNITY; DENDRITIC CELLS; DIABETES MELLITUS, TYPE 1; HUMANS; IMMUNITY, NATURAL; INTERFERON TYPE I; LUPUS ERYTHEMATOSUS, SYSTEMIC; MEMBRANE GLYCOPROTEINS; MEMBRANE PROTEINS; MODELS, IMMUNOLOGICAL; RECEPTOR, INTERFERON ALPHA-BETA; RECEPTORS, CELL SURFACE; RECEPTORS, INTERFERON; SIGNAL TRANSDUCTION; TOLL-LIKE RECEPTORS;

EID: 17644402442     PISSN: 07320582     EISSN: None     Source Type: Book Series    
DOI: 10.1146/annurev.immunol.23.021704.115843     Document Type: Review

References (176)

1. Stark GR, Kerr IM, Williams BR, Silverman RH, Schreiber RD. 1998. How cells respond to interferons. Annu. Rev. Biochem. 67:227-64
2. Pestka S. 2000. The human interferon α species and receptors. Biopolymers 55:254-87
3. Biron CA. 2001. Interferons α and β as immune regulators-a new look. Immunity 14:661-64
4. Der SD, Zhou A, Williams BR, Silverman RH. 1998. Identification of genes differentially regulated by interferon α, β, or γ using oligonucleotide arrays. Proc. Natl. Acad. Sci. USA 95:15623-28
5. Baechler EC, Batliwalla FM, Karypis G, Gaffney PM, Ortmann WA, et al. 2003. Interferon-inducible gene expression signature in peripheral blood cells of patients with severe lupus. Proc. Natl. Acad. Sci. USA 100:2610-15
6. Bennett L, Palucka AK, Arce E, Cantrell V, Borvak I, et al. 2003. Interferon and granulopoiesis signatures in systemic lupus erythematosus blood. J. Exp. Med. 197:711-23
7. Pestka S, Krause CD, Sarkar D, Walter MR, Shi Y, et al. 2004. Interleukin-10 and related cytokines and receptors. Annu. Rev. Immunol. 22:929-79
8. Donnelly RP, Sheikh F, Kotenko SV, Dickensheets H. 2004. The expanded family of class II cytokines that share the IL-10 receptor-2 (IL-10R2) chain. J. Leukoc. Biol 76:314-21
9. Kotenko SV, Langer JA. 2004. Full house: 12 receptors for 27 cytokines. Int. Immunopharmacol. 4:593-608
10. Schlaak JF, Hilkens CM, Costa-Pereira AP, Strobl B, Aberger F, et al. 2002. Cell-type and donor-specific transcriptional responses to interferon-α. Use of customized gene arrays. J. Biol. Chem. 277:49428-37
11. Kotenko SV, Gallagher G, Baurin VV, Lewis-Antes A, Shen M, et al. 2003. IFN-λs mediate antiviral protection through a distinct class II cytokine receptor complex. Nat. Immunol. 4:69-77
12. Sheppard P, Kindsvogel W, Xu W, Henderson K, Schlutsmeyer S, et al. 2003. IL-28, IL-29 and their class II cytokine receptor IL-28R. Nat. Immunol. 4:63-68
13. Shuai K, Liu B. 2003. Regulation of JAK-STAT signalling in the immune system. Nat. Rev. Immunol. 3:900-11
14. Hata N, Sato M, Takaoka A, Asagiri M, Tanaka N, et al. 2001. Constitutive IFN-α/β signal for efficient IFN-α/β gene induction by virus. Biochem. Biophys. Res. Commun. 285:518-25
15. Taniguchi T, Takaoka A. 2001. A weak signal for strong responses: interferon-α/βrevisited. Nat. Rev. Mol. Cell Biol. 2:378-86
16. Takaoka A, Mitani Y, Suemori H, Sato M, Yokochi T, et al. 2000. Cross talk between interferon-γ and -α/β signaling components in caveolar membrane domains. Science 288:2357-60
17. Montoya M, Schiavoni G, Mattei F, Gresser I, Belardelli F, et al. 2002. Type I interferons produced by dendritic cells promote their phenotypic and functional activation. Blood 99:3263-71
18. + T cells. J. Exp. Med. 178:1655-63
19. Santiago-Raber ML, Baccala R, Haraldsson KM, Choubey D, Stewart TA, et al. 2003. Type-I interferon receptor deficiency reduces lupus-like disease in NZB mice. J. Exp. Med. 197:777-88
20. Cousens LP, Peterson R, Hsu S, Dorner A, Altman JD, et al. 1999. Two roads diverged: interferon α/β- and interleukin 12-mediated pathways in promoting T cell interferon γ responses during viral infection. J. Exp. Med. 189:1315-28
21. Nguyen KB, Cousens LP, Doughty LA, Pien GC, Durbin JE, et al. 2000. Interferon α/β-mediated inhibition and promotion of interferon γ: STAT1 resolves a paradox. Nat. Immunol. 1:70-76
22. Nguyen KB, Watford WT, Salomon R, Hofmann SR, Pien GC, et al. 2002. Critical role for STAT4 activation by type 1 interferons in the interferon-γ response to viral infection. Science 297:2063-66
23. Darnell JE Jr, Kerr IM, Stark GR. 1994. Jak-STAT pathways and transcriptional activation in response to IFNs and other extracellular signaling proteins. Science 264:1415-21
24. Levy DE, Lew DJ, Decker T, Kessler DS, Darnell JE Jr. 1990. Synergistic interaction between interferon-α and interferon- γ through induced synthesis of one subunit of the transcription factor ISGF3. EMBO J. 9:1105-11
25. Tassiulas I, Hu X, Ho H, Kashyap Y, Paik P, Hu Y, et al. 2004. Amplification of IFN-α-induced STAT1 activation and inflammatory function by Syk and ITAM-containing adaptors. Nat. Immunol. 5:1181-89
26. Brassard DL, Grace MJ, Bordens RW. 2002. Interferon-α as an immunotherapeutic protein. J. Leukoc. Biol. 71:565-81
27. Mitani Y, Takaoka A, Kim SH, Kato Y, Yokochi T, et al. 2001. Cross talk of the interferon-α/β signalling complex with gp130 for effective interleukin-6 signalling. Genes Cells 6:631-40
28. Dickensheets HL, Venkataraman C, Schindler U, Donnelly RP. 1999. Interferons inhibit activation of STAT6 by interleukin 4 in human monocytes by inducing SOCS-1 gene expression. Proc. Natl. Acad. Sci USA 96:10800-5
29. + T cells in vivo by IL-15. Immunity 8:591-99
30. Ito S, Ansari P, Sakatsume M, Dickensheets H, Vazquez N, et al. 1999. Interleukin-10 inhibits expression of both Interferon α- and interferon γ-induced genes by suppressing tyrosine phosphorylation of STAT1. Blood 93:1456-63
31. Sharif MN, Tassiulas I, Hu Y, Mecklenbrauker I, Tarakhovsky A, et al. 2004. IFN-α priming results in a gain of proinflammatory function by IL-10: implications for systemic lupus erythematosus pathogenesis. J. Immunol. 172:6476-81
32. Llorente L, Richaud-Patin Y. 2003. The role of interleukin-10 in systemic lupus erythematosus. J. Autoimmun. 20:287-89
33. Ishida H, Muchamuel T, Sakaguchi S, Andrade S, Menon S, et al. 1994. Continuous administration of anti-interleukin 10 antibodies delays onset of autoimmunity in NZB/W F1 mice. J. Exp. Med. 179:305-10
34. Ivashkiv LB. 2003. Type I interferon modulation of cellular responses to cytokines and infectious pathogens: potential role in SLE pathogenesis. Autoimmunity 36:473-79
35. Banchereau J, Pascual V, Palucka AK. 2004. Autoimmunity through cytokine-induced dendritic cell activation. Immunity 20:539-50
36. Theofilopoulos AN, Lawson BR. 1999. Tumour necrosis factor and other cytokines in murine lupus. Ann. Rheum. Dis. 58(Suppl. 1):I49-55
37. Aringer M, Smolen JS. 2003. SLE-Complex cytokine effects in a complex autoimmune disease: tumor necrosis factor in systemic lupus erythematosus. Arthritis Res. Ther. 5:172-77
38. O'Shea JJ, Gadina M, Schreiber RD. 2002. Cytokine signaling in 2002: new surprises in the Jak/Stat pathway. Cell 109(Suppl):S121-31
39. Takaoka A, Hayakawa S, Yanai H, Stoiber D, Negishi H, et al. 2003. Integration of interferon-α/β signalling to p53 responses in tumour suppression and antiviral defence. Nature 424:516-23
40. Colonna M, Krug A, Cella M. 2002. Interferon-producing cells: on the front line in immune responses against pathogens. Curr. Opin. Immunol. 14:373-79
41. Coccia EM, Severa M, Giacomini E, Monneron D, Remoli ME, et al. 2004. Viral infection and Toll-like receptor agonists induce a differential expression of type I and λ interferons in human plasmacytoid and monocyte-derived dendritic cells. Eur. J. Immunol. 34:796-805
42. Shortman K, Liu YJ. 2002. Mouse and human dendritic cell subtypes. Nat. Rev. Immunol. 2:151-61
43. del Hoyo GM, Martin P, Vargas HH, Ruiz S, Arias CF, et al. 2002. Characterization of a common precursor population for dendritic cells. Nature 415:1043-47
44. a. Shigematsu H, Reizis B, Iwasaki H, Mizuno S, Hu D, et al. 2004. Plasmacytoid dendritic cells activate lymphoid-specific genetic programs irrespective of their cellular origin. Immunity 21:43-53
45. Dzionek A, Inagaki Y, Okawa K, Nagafune J, Rock J, et al. 2002. Plasmacytoid dendritic cells: from specific surface markers to specific cellular functions. Hum. Immunol. 63:1133-48
46. Blomberg S, Eloranta ML, Magnusson M, Alm GV, Ronnblom L. 2003. Expression of the markers BDCA-2 and BDCA-4 and production of interferon-α by plasmacytoid dendritic cells in systemic lupus erythematosus. Arthritis. Rheum. 48:2524-32
47. Asselin-Paturel C, Brizard G, Pin JJ, Briere F, Trinchieri G. 2003. Mouse strain differences in plasmacytoid dendritic cell frequency and function revealed by a novel monoclonal antibody. J. Immunol. 171:6466-77
48. + dendritic cells endowed with type 1 interferon production capacity and tolerogenic potential. Blood 100:383-90
49. + cells in mouse lymph nodes and spleen display characteristics of plasmacytoid dendritic cells. J. Exp. Med. 194:1171-78
50. Bjorck P. 2001. Isolation and characterization of plasmacytoid dendritic cells from Flt3 ligand and granulocyte-macrophage colony-stimulating factor-treated mice. Blood 98:3520-26
51. Gilliet M, Boonstra A, Paturel C, Antonenko S, Xu XL, et al. 2002. The development of murine plasmacytoid dendritic cell precursors is differentially regulated by FLT3-ligand and granulocyte/macrophage colony-stimulating factor. J. Exp. Med. 195:953-58
52. D'Amico A, Wu L. 2003. The early progenitors of mouse dendritic cells and plasmacytoid predendritic cells are within the bone marrow hemopoietic precursors expressing Flt3. J. Exp. Med. 198:293-303
53. Izaguirre A, Barnes BJ, Amrute S, Yeow WS, Megjugorac N, et al. 2003. Comparative analysis of IRF and IFN-α expression in human plasmacytoid and monocyte-derived dendritic cells. J. Leukoc. Biol. 74:1125-38
54. Santini SM, Di Pucchio T, Lapenta C, Parlato S, Logozzi M, et al. 2002. The natural alliance between type I interferon and dendritic cells and its role in linking innate and adaptive immunity. J. Interferon Cytokine Res. 22:1071-80
55. Diebold SS, Montoya M, Unger H, Alexopoulou L, Roy P, et al. 2003. Viral infection switches non-plasmacytoid dendritic cells into high interferon producers. Nature 424:324-28
56. Taniguchi T, Ogasawara K, Takaoka A, Tanaka N. 2001. IRF family of transcription factors as regulators of host defense. Annu. Rev. Immunol. 19:623-55
57. Sato M, Taniguchi T, Tanaka N. 2001. The interferon system and interferon regulatory factor transcription factors-studies from gene knockout mice. Cytokine Growth Factor Rev. 12:133-42
58. + T) cells, natural killer cells, and intestinal intraepithelial T cells. J. Exp. Med. 187:967-72
59. Ogasawara K, Hida S, Azimi N, Tagaya Y, Sato T, et al. 1998. Requirement for IRF-1 in the microenvironment supporting development of natural killer cells. Nature 391:700-3
60. Matsuyama T, Kimura T, Kitagawa M, Pfeffer K, Kawakami T, et al. 1993. Targeted disruption of IRF-1 or IRF-2 results in abnormal type I IFN gene induction and aberrant lymphocyte development. Cell 75:83-97
61. + thymocytes. Immunity 7:243-54
62. Taki S, Sato T, Ogasawara K, Fukuda T, Sato M, et al. 1997. Multistage regulation of Th1-type immune responses by the transcription factor IRF-1. Immunity 6:673-79
63. Lohoff M, Ferrick D, Mittrucker HW, Duncan GS, Bischof S, et al. 1997. Interferon regulatory factor-1 is required for a T helper 1 immune response in vivo. Immunity 6:681-89
64. Tada Y, Ho A, Matsuyama T, Mak TW. 1997. Reduced incidence and severity of antigen-induced autoimmune diseases in mice lacking interferon regulatory factor-1 J. Exp. Med. 185:231-38
65. Nakazawa T, Satoh J, Takahashi K, Sakata Y, Ikehata F, et al. 2001. Complete suppression of insulitis and diabetes in NOD mice lacking interferon regulatory factor-1. J. Autoimmun. 17:119-25
66. Lohoff M, Duncan GS, Ferrick D, Mittrucker HW, Bischof S, et al. 2000. Deficiency in the transcription factor interferon regulatory factor (IRF)-2 leads to severely compromised development of natural killer and T helper type 1 cells. J. Exp. Med. 192:325-36
67. + T cell-mediated skin disease in mice lacking IRF-2, the transcriptional attenuator of interferon-α/β signaling. Immunity 13:643-55
68. Mittrucker HW, Matsuyama T, Grossman A, Kundig TM, Potter J, et al. 1997. Requirement for the transcription factor LSIRF/IRF4 for mature B and T lymphocyte function. Science 275:540-43
69. Lohoff M, Mittrucker HW, Prechtl S, Bischof S, Sommer F, et al. 2002. Dysregulated T helper cell differentiation in the absence of interferon regulatory factor 4. Proc. Natl. Acad. Sci. USA 99:11808-12
70. + dendritic cells. J. Exp. Med. 196:1415-25
71. Tsujimura H, Tamura T, Ozato K. 2003. Cutting edge: IFN consensus sequence binding protein/IFN regulatory factor 8 drives the development of type I IFN-producing plasmacytoid dendritic cells. J. Immunol. 170:1131-35
72. Tsujimura H, Tamura T, Kong HJ, Nishiyama A, Ishii KJ, et al. 2004. Toll-like receptor 9 signaling activates NF-κB through IFN regulatory factor-8/IFN consensus sequence binding protein in dendritic cells. J. Immunol. 172:6820-27
73. Choubey D, Kotzin BL. 2002. Interferon-inducible p202 in the susceptibility to systemic lupus. Front. Biosci. 7:e252-62
74. Rozzo SJ, Allard JD, Choubey D, Vyse TJ, Izui S, et al. 2001. Evidence for an interferon-inducible gene, Ifi202, in the susceptibility to systemic lupus. Immunity 15:435-43
75. Takeda K, Kaisho T, Akira S. 2003. Toll-like receptors, Annu. Rev. Immunol. 21:335-76
76. Beutler B, Hoebe K, Du X, Ulevitch RJ. 2003. How we detect microbes and respond to them: the Toll-like receptors and their transducers. J Leukoc. Biol. 74:479-85
77. a. Iwasaki A, Medzhitov R. 2004. Toll-like receptor control of the adaptive immune responses. Nat. Immunol. 5:987-95
78. Hoebe K, Du X, Georgel P, Janssen E, Tabeta K, et al. 2003. Identification of Lps2 as a key transducer of MyD88-independent TIR signalling. Nature 424:743-48
79. Yamamoto M, Sato S, Hemmi H, Hoshino K, Kaisho T, et al. 2003. Role of adaptor TRIF in the MyD88-independent toll-like receptor signaling pathway. Science 301:640-43
80. Yamamoto M, Sato S, Hemmi H, Uematsu S, Hoshino K, et al. 2003. TRAM is specifically involved in the Toll-like receptor 4-mediated MyD88-independent signaling pathway. Nat. Immunol. 4:1144-50
81. Hoebe K, Janssen EM, Kim SO, Alexopoulou L, Flavell RA, et al. 2003. Upregulation of costimulatory molecules induced by lipopolysaccharide and double-stranded RNA occurs by Trif-dependent and Trif-independent pathways. Nat. Immunol. 4:1223-29
82. a. McGettrick AF, O'Neill LA. 2004. The expanding family of MyD88-like adaptors in Toll-like receptor signal transduction. Mol. Immunol. 41:577-82
83. Leadbetter EA, Rifkin IR, Hohlbaum AM, Beaudette BC, Shlomchik MJ, et al. 2002. Chromatin-IgG complexes activate B cells by dual engagement of IgM and Toll-like receptors. Nature 416:603-07
84. Viglianti GA, Lau CM, Hanley TM, Miko BA, Shlomchik MJ, et al. 2003. Activation of autoreactive B cells by CpG dsDNA. Immunity 19:837-47
85. Heil F, Hemmi H, Hochrein H, Ampenberger F, Kirschning C, et al. 2004. Species-specific recognition of single-stranded RNA via Toll-like receptor 7 and 8. Science 303:1526-29
86. O'Neill LA. 2004. After the Toll rush. Science 303:1481-82
87. Wloch MK, Alexander AL, Pippen AM, Pisetsky DS, Gilkeson, et al. 1997. Molecular properties of anti-DNA induced in preautoimmune NZB/W mice by immunization with bacterial DNA. J. Immunol. 158:4500-6
88. Hang L, Slack JH, Amundson C, Izui S, Theofilopoulos AN, et al. 1983. Induction of murine autoimmune disease by chronic polyclonal B cell activation. J. Exp. Med. 157:874-83
89. Rui L, Vinuesa CG, Blasioli J, Goodnow CC. 2003. Resistance to CpG DNA-induced autoimmunity through tolerogenic B cell antigen receptor ERK signaling. Nat. Immunol. 4:594-600
90. Waldner H, Collins M, Kuchroo VK. 2004. Activation of antigen-presenting cells by microbial products breaks self tolerance and induces autoimmune_disease. J. Clin. Invest. 113:990-97
91. Turley S, Poirot L, Hattori M, Benoist C, Mathis D. 2003. Physiological β cell death triggers priming of self-reactive T cells by dendritic cells in a type-1 diabetes model. J Exp. Med. 198:1527-37
92. Horwitz MS, Bradley LM, Harbertson J, Krahl T, Lee J, et al. 1998. Diabetes induced by Coxsackie virus: initiation by bystander damage and not molecular mimicry. Nat. Med. 4:781-85
93. Le Bon A, Tough DF. 2002. Links between innate and adaptive immunity via type I interferon. Curr. Opin. Immunol. 14:432-36
94. + T cells stimulated by virus-induced type I interferon. Nat. Immunol. 4:1009-15
95. Marrack P, Kappler J, Mitchell T. 1999. Type I interferons keep activated T cells alive. J. Exp. Med. 189:521-30
96. Tough DF, Borrow P, Sprent J. 1996. Induction of bystander T cell proliferation by viruses and type I interferon in vivo. Science 272:1947-50
97. + T cell activation. Genes Cells 7:309-20
98. Lee CK, Rao DT, Gertner R, Gimeno R, Frey AB, et al. 2000. Distinct requirements for IFNs and STAT1 in NK cell function. J. Immunol. 165:3571-77
99. Chawla-Sarkar M, Lindner DJ, Liu YF, Williams BR, Sen GC, et al. 2003. Apoptosis and interferons: role of interferon-stimulated genes as mediators of apoptosis. Apoptosis 8:237-49
100. Dondi E, Rogge L, Lutfalla G, Uze G, Pellegrini S. 2003. Down-modulation of responses to type I IFN upon T cell activation. J. Immunol. 170:749-56
101. Carrero JA, Calderon B, Unanue ER. 2004. Type I interferon sensitizes lymphocytes to apoptosis and reduces resistance to Listeria infection. J. Exp. Med. 200:535-40
102. O'Connell RM, Saha SK, Vaidya SA, Bruhn KW, Miranda GA, et al. 2004. Type I interferon production enhances susceptibility to Listeria monocytogenes infection. J. Exp. Med. 200:437-45
103. Auerbuch V, Brockstedt DG, Meyer-Morse N, O'Riordan M, Portnoy DA. 2004. Mice lacking the type I interferon receptor are resistant to Listeria monocytogenes. J. Exp. Med. 200:527-33
104. Braun D, Caramalho I, Demengeot J. 2002. IFN-α/β enhances BCR-dependent B cell responses. Int. Immunol. 14:411-19
105. Le Bon A, Schiavoni G, D'Agostino G, Gresser I, Belardelli F, et al. 2001. Type I interferons potently enhance humoral immunity and can promote isotype switching by stimulating dendritic cells in vivo. Immunity 14:461-70
106. Litinskiy MB, Nardelli B, Hilbert DM, He B, Schaffer A, et al. 2002. DCs induce CD40-independent immunoglobulin class switching through BLyS and APRIL. Nat. Immunol. 3:822-29
107. Jego G, Palucka AK, Blanck JP, Chalouni C, Pascual V, et al. 2003. Plasmacytoid dendritic cells induce plasma cell differentiation through type I interferon and interleukin 6. Immunity 19:225-34
108. MacLennan I, Vinuesa C. 2002. Dendritic cells, BAFF, and APRIL: innate players in adaptive antibody responses. Immunity 17:235-38
109. Khare SD, Sarosi I, Xia XZ, McCabe S, Miner K, et al. 2000. Severe B cell hyperplasia and autoimmune disease in TALL-1 transgenic mice. Proc. Natl. Acad. Sci. USA 97:3370-75
110. Mackay F, Woodcock SA, Lawton P, Ambrose C, Baetscher M, et al. 1999. Mice transgenic for BAFF develop lymphocytic disorders along with autoimmune manifestations. J. Exp. Med. 190:1697-710
111. Seshasayee D, Valdez P, Yan M, Dixit VM, Tumas D, et al. 2003. Loss of TACI causes fatal lymphoproliferation and autoimmunity, establishing TACI as an inhibitory BLyS receptor. Immunity 18:279-88
112. Kanada T, Yoshida H, Kato S, Tanaka K, Masutani K, et al. 2003. Suppressor of cytokine signaling-1 is essential for suppressing dendritic cell activation and systemic autoimmunity. Immunity 19:437-50
113. Gross JA, Johnston J, Mudri S, Enselman R, Dillon SR, et al. 2000. TACI and BCMA are receptors for a TNF homologue implicated in B-cell autoimmune disease. Nature 404:995-99
114. Liu W, Szalai A, Zhao L, Liu D, Martin F, et al. 2004. Control of spontaneous B lymphocyte autoimmunity with adenovirus-encoded soluble TACI. Arthritis Rheum. 50:1884-96
115. Stohl W. 2004. A therapeutic role for BLyS antagonists. Lupus 13:317-22
116. Lin Q, Dong C, Cooper MD. 1998. Impairment of T and B cell development by treatment with a type I interferon. J. Exp. Med. 187:79-87
117. Hooks JJ, Moutsopoulos HM, Geis SA, Stahl NI, Decker JL, et al. 1979. Immune interferon in the circulation of patients with autoimmune disease. N. Engl. J. Med. 301:5-8
118. Ronnblom L, Alm GV. 2001. An etiopathogenic role for the type I IFN system in SLE. Trends Immunol. 22:427-31
119. Bengtsson AA, Sturfeh G, Truedsson L, Blomberg J, Alm G, et al. 2000. Activation of type I interferon system in systemic lupus erythematosus correlates with disease activity but not with antiretroviral antibodies. Lupus 9:664-71
120. Gota C, Calabrese L. 2003. Induction of clinical autoimmune disease by therapeutic interferon-α. Autoimmunity 36:511-18
121. Blanco P, Palucka AK, Gill M, Pascual V, Banchereau J. 2001. Induction of dendritic cell differentiation by IFN-α in systemic lupus erythematosus. Science 294:1540-43
122. Han GM, Chen SL, Shen N, Ye S, Bao CD, et al. 2003. Analysis of gene expression profiles in human systemic lupus erythematosus using oligonucleotide microarray. Genes Immun. 4:177-86
123. Alcorta D, Preston G, Munger W, Sullivan P, Yang JJ, et al. 2002. Microarray studies of gene expression in circulating leukocytes in kidney diseases. Exp. Nephrol. 10:139-49
124. Crow MK. 2003. Interferon-α: a new target for therapy in systemic lupus erythematosus? Arthritis Rheum. 48:2396-401
125. Peterson KS, Huang JF, Zhu J, D'Agati V, Liu X, et al. 2004. Characterization of heterogeneity in the molecular pathogenesis of lupus nephritis from transcriptional profiles of laser-captured glomeruli. J. Clin. Invest. 113:1722-33
126. Ronnblom L, Eloranta ML, Alm GV. 2003. Role of natural interferon-α producing cells (plasmacytoid dendritic cells) in autoimmunity. Autoimmunity 36:463-72
127. Lovgren T, Eloranta ML, Bave U, Alm GV, Ronnblom L. 2004. Induction of interferon-α production in plasmacytoid dendritic cells by immune complexes containing nucleic acid released by necrotic or late apoptotic cells and lupus IgG. Arthritis Rheum. 50:1861-72
128. Heremans H, Billiau A, Colombatti A, Hilgers J, de Somer P. 1978. Interferon treatment of NZB mice: accelerated progression of autoimmune disease. Infect. Immun. 21:925-30
129. Adam C, Thoua Y, Ronco P, Verroust P, Tovey M, et al. 1980. The effect of exogenous interferon: acceleration of autoimmune and renal diseases in (NZB/W) F1 mice. Clin. Exp. Immunol. 40:373-82
130. Sergiescu D, Cerutti I, Efthymiou E, Kahan A, Chany C. 1979. Adverse effects of interferon treatment on the life span of NZB mice. Biomedicine 31:48-51
131. Hasegawa K, Hayashi T. 2003. Synthetic CpG oligodeoxynucleotides accelerate the development of lupus nephritis during preactive phase in NZB x NZWF1 mice. Lupus 12:838-45
132. Kono DH, Baccala R, Theofilopoulos AN. 2004. Genes and genetics of murine lupus. In Systemic Lupus Erythematosus, ed. RG Lahita, pp. 225-63. San Diego: Elsevier
133. Pramanik R, Jorgensen TN, Xin H, Kotzin BL, Choubey D. 2004. Interleukin-6 induces expression of Ifi202, an interferon-inducible candidate gene for lupus susceptibility. J. Biol. Chem. 279:16121-27
134. Theofilopoulos AN, Koundouris S, Kono DH, Lawson BR. 2001. The role of IFN-γ in systemic lupus erythematosus: a challenge to the Th1/Th2 paradigm in autoimmunity. Arthritis Res. 3:136-41
135. Braun D, Geraldes P, Demengeot J. 2003. Type I interferon controls the onset and severity of autoimmune manifestations in lpr mice. J. Autoimmun. 20:15-25
136. Hron JD, Peng SL. 2004. Type I IFN protects against murine lupus. J. Immunol. 173:2134-42
137. Stewart TA. 2003. Neutralizing interferon α as a therapeutic approach to autoimmune diseases. Cytokine Growth Factor Rev. 14:139-54
138. Devendra D, Eisenbarth GS. 2004. Interferon α-a potential link in the pathogenesis of viral-induced type 1 diabetes and autoimmunity. Clin. Immunol. 111:225-33
139. Huang X, Yuang J, Goddard A, Foulis A, James RF, et al. 1995. Interferon expression in the pancreases of patients with type 1 diabetes. Diabetes 44:658-64
140. Fabris P, Floreani A, Tositti G, Vergani D, De Lalla F, et al. 2003. Type 1 diabetes mellitus in patients with chronic hepatitis C before and after interferon therapy. Aliment. Pharmacol. Ther. 18:549-58
141. Guerci AP, Guerci B, Levy-Marchal C, Ongagna J, Ziegler O, et al. 1994. Onset of insulin-dependent diabetes mellitus after interferon-α therapy for hairy cell leukaemia. Lancet 343:1167-68
142. Chehadeh W, Weill J, Vantyghem MC, Alm G, Lefebvre J, et al. 2000. Increased level of interferon-α in blood of patients with insulin-dependent diabetes mellitus: relationship with coxsackievirus B infection. J. Infect. Dis. 181:1929-39
143. Stewart TA, Hultgren B, Huang X, Pitts-Meek S, Hully J, et al. 1993. Induction of type I diabetes by interferon-α in transgenic mice. Science 260:1942-46
144. Pelegrin M, Devedjian JC, Costa C, Visa J, Solanes G, et al. 1998. Evidence from transgenic mice that interferon-β may be involved in the onset of diabetes mellitus. J. Biol. Chem. 273:12332-40
145. Vassileva G, Chen SC, Zeng M, Abbondanzo S, Jensen K, et al. 2003. Expression of a novel murine type I IFN in the pancreatic islets induces diabetes in mice. J. Immunol. 170:5748-55
146. Ewel CH, Sobel DO, Zeligs BJ, Belland JA. 1992. Poly I:C accelerates development of diabetes mellitus in diabetes-prone BB rat. Diabetes 41:1016-21
147. Huang X, Hultgren B, Dybdal N, Stewart TA. 1994. Islet expression of interferon- α precedes diabetes in both the BB rat and streptozotocin-treated mice. Immunity 1:469-78
148. Giron DJ, Agostini HJ, Thomas DC. 1988. Effect of interferons and poly(I):poly(C) on the pathogenesis of the diabetogenic variant of encephalomyocarditis virus in different mouse strains. J. Interferon. Res. 8:745-53
149. Moriyama H, Wen L, Abiru N, Liu E, Yu L, et al. 2002. Induction and acceleration of insulitis/diabetes in mice with a viral mimic (polyinosinic-polycytidylic acid) and an insulin self-peptide. Proc. Natl. Acad. Sci. USA 99:5539-44
150. Paronen J, Liu E, Moriyama H, Devendra D, Ide A, et al. 2004. Genetic differentiation of poly I:C from B:9-23 peptide induced experimental autoimmune diabetes. J. Autoimmun. 22:307-13
151. Sobel DO, Ahvazi B. 1998. Alpha-interferon inhibits the development of diabetes in NOD mice. Diabetes 47:1867-72
152. Sobel DO, Creswell K, Yoon JW, Holterman D. 1998. Alpha interferon administration paradoxically inhibits the development of diabetes in BB rats. Life Sci. 62:1293-302
153. Serreze DV, Hamaguchi K, Leiter EH. 1989. Immunostimulation circumvents diabetes in NOD/Lt mice. J. Autoimmun. 2:759-76
154. Sobel DO, Goyal D, Ahvazi B, Yoon JW, Chung YH, et al. 1998. Low dose poly I:C prevents diabetes in the diabetes prone BB rat. J. Autoimmim. 11:343-52
155. Tanaka-Kataoka M, Kunikata T, Takayama S, Iwaki K, Fujii M, et al. 1999. Oral use of interferon-α delays the onset of insulin-dependent diabetes mellitus in nonobese diabetes mice. J. Interferon Cytokine Res. 19:877-79
156. Brod SA. 2002. Ingested type I interferon: a potential treatment for autoimmunity. J. Interferon Cytokine Res. 22:1153-66
157. Yang XD, Tisch R, Singer SM, Cao ZA, Liblau RS, et al. 1994. Effect of tumor necrosis factor α on insulin-dependent diabetes mellitus in NOD mice. I. The early development of autoimmunity and the diabetogenic process. J. Exp. Med. 180:995-1004
158. King C, Ilic A, Koelsch K, Sarvetnick N. 2004. Homeostatic expansion of T cells during immune insufficiency generates autoimmunity. Cell 117:265-77
159. Theofilopoulos AN, Dummer W, Kono DH. 2001. T cell homeostasis and systemic autoimmunity. J. Clin. Invest. 108:335-40
160. Jaeckel E, Manns M, Von Herrath M. 2002. Viruses and diabetes. Ann. N.Y. Acad. Sci. 958:7-25
161. Sevilla N, McGavern DB, Teng C, Kunz S, Oldstone MB. 2004. Viral targeting of hematopoietic progenitors and inhibition of DC maturation as a dual strategy for immune subversion. J. Clin. Invest. 113:737-45
162. Oldstone MB. 1990. Viruses as therapeutic agents. I. Treatment of nonobese insulin-dependent diabetes mice with virus prevents insulin-dependent diabetes mellitus while maintaining general immune competence. J. Exp. Med. 171:2077-89
163. Christen U, Benke D, Wolfe T, Rodrigo E, Rhode A, et al. 2004. Cure of prediabetic mice by viral infections involves lymphocyte recruitment along an IP-10 gradient. J. Clin. Invest. 113:74-84
164. Hafler DA. 2004. Multiple sclerosis. J. Clin. Invest. 113:788-94
165. Teige I, Treschow A, Teige A, Mattsson R, Navikas V, et al. 2003. IFN-β gene deletion leads to augmented and chronic demyelinating experimental autoimmune encephalomyelitis. J. Immunol. 170:4776-84
166. Passos de Souza E, Evangelista Segundo PT, Jose FF, Lemaire D, Santiago M. 2001. Rheumatoid arthritis induced by α-interferon therapy. Clin. Rheumatol. 20:297-99
167. Van Holten J, Reedquist K, Sattonet-Roche P, Smeets TJ, Plater-Zyberk C, et al. 2004. Treatment with recombinant interferon-β reduces inflammation and slows cartilage destruction in the collagen-induced arthritis model of rheumatoid arthritis. Arthritis Res. Ther. 6:R239-49
168. Tak PP, Hart BA, Kraan MC, Jonker M, Smeets TJ, et al. 1999. The effects of interferon β treatment on arthritis. Rheumatology 38:362-69
169. van Holten J, Plater-Zyberk C, Tak PP. 2002. Interferon-β for treatment of rheumatoid arthritis? Arthritis Res. 4:346-52
170. Cummins MJ, Papas A, Kammer GM, Fox PC. 2003. Treatment of primary Sjögren's syndrome with low-dose human interferon α administered by the oromucosal route: combined phase III results. Arthritis Rheum. 49:585-93
171. Borgia G, Reynaud L, Gentile I, Cerini R, Ciampi R, et al. 2001. Myasthenia gravis during low-dose IFN-α therapy for chronic hepatitis C. J. Interferon Cytokine Res. 21:469-70
172. Deng C, Goluszko E, Baron S, Wu B, Christadoss P. 1996. IFN-α therapy is effective in suppressing the clinical experimental myasthenia gravis. J. Immunol. 157:5675-82
173. Andriani A,Bibas M, Callea V, De Renzo A, Chiurazzi F, et al. 1996. Autoimmune hemolytic anemia during α interferon treatment in nine patients with hematological diseases. Haematologica 81:258-60
174. Kawai T, Sato S, Ishii KJ, Coban C, Hemmi H, et al. 2004. Interferon-α induction through Toll-like receptors involves a direct interaction of IRF7 with MyD88 and TRAF6. Nat. Immunol. 5:1061-68
175. Barchet W, Cella M, Odermatt B, Asselin-Paturel C, Colonna M, Kalinke U. 2002. Virus-induced interferon α production by a dendritic cell subset in the absence of feedback signaling in vivo. J. Exp. Med. 195:507-16
176. Liu Y-J. 2005. IPC: Professional type 1 interferon-producing cells and plasmacytoid dendritic cell precursors. Annu. Rev. Immunol. 23:275-306